UK Markets open in 5 hrs 29 mins

Infinity Pharmaceuticals, Inc. (INFI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.1900+0.0200 (+1.71%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 106.69M
Enterprise value 51.30M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)48.01
Price/book (mrq)8.03
Enterprise value/revenue 23.14
Enterprise value/EBITDA -1.11

Trading information

Stock price history

Beta (5Y monthly) 2.09
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 33.5000
52-week low 30.4600
50-day moving average 31.1754
200-day moving average 31.1154

Share statistics

Avg vol (3-month) 3542.81k
Avg vol (10-day) 3376.97k
Shares outstanding 589.02M
Implied shares outstanding 6N/A
Float 875.79M
% held by insiders 11.25%
% held by institutions 144.71%
Shares short (14 Jul 2022) 41.38M
Short ratio (14 Jul 2022) 41.54
Short % of float (14 Jul 2022) 41.58%
Short % of shares outstanding (14 Jul 2022) 41.55%
Shares short (prior month 14 Jun 2022) 44.45M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:4
Last split date 312 Sept 2006

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin 0.00%
Operating margin (ttm)-2,247.09%

Management effectiveness

Return on assets (ttm)-31.02%
Return on equity (ttm)-148.54%

Income statement

Revenue (ttm)2.04M
Revenue per share (ttm)0.02
Quarterly revenue growth (yoy)39.60%
Gross profit (ttm)-30.91M
EBITDA -45.43M
Net income avi to common (ttm)-46.07M
Diluted EPS (ttm)-0.6760
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)67.14M
Total cash per share (mrq)0.75
Total debt (mrq)1.31M
Total debt/equity (mrq)13.16
Current ratio (mrq)5.23
Book value per share (mrq)-0.36

Cash flow statement

Operating cash flow (ttm)-40.68M
Levered free cash flow (ttm)-21.83M